The biomanufacturing industry is undergoing a major shift, from single-product processes and stainless-steel infrastructure to flexible, multi-product facilities using single-use technology. Though single-use is being widely adopted, there still exists a lag in automation and measurement to make the most use of the technology and data integration. The next set of biomanufacturing challenges go handin-hand: (1) the scale-down of the bioprocess, and (2) perfusion/continuous processing (CP). The first is driven by the fact that production titers continue to increase; a 6 g/L titer is not uncommon anymore, and this figure is already past the limit of a lot downstream processing capabilities. The progress in production titers has created a gap in single-use processing, where the upstream productivity is mismatched with the throughput and capacity of the downstream equipment.